Recent News

• 06.03.2025 - Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
• 06.03.2025 - Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
• 05.31.2025 - New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
• 05.31.2025 - Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
• 05.29.2025 - Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
• 05.27.2025 - Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
• 05.27.2025 - Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
• 05.27.2025 - Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
• 05.22.2025 - Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
• 05.20.2025 - Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Recent Filings

• 06.03.2025 - 144 Report of proposed sale of securities
• 06.02.2025 - SD Specialized disclosure report
• 05.28.2025 - 8-K Current report
• 05.22.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.22.2025 - 8-K Current report
• 05.22.2025 - EX-99.1 EX-99.1
• 05.20.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses